Home>>Signaling Pathways>> Tyrosine Kinase>> EGFR>>WHI-P180 hydrochloride

WHI-P180 hydrochloride Sale

(Synonyms: Janex 3 hydrochloride;) 目录号 : GC37933

A multi-kinase inhibitor

WHI-P180 hydrochloride Chemical Structure

Cas No.:153437-55-9

规格 价格 库存 购买数量
2mg
¥1,440.00
现货
5mg
¥2,250.00
现货
10mg
¥3,420.00
现货
50mg
¥8,100.00
现货

电话:400-920-5774 Email: sales@glpbio.cn

Customer Reviews

Based on customer reviews.

Sample solution is provided at 25 µL, 10mM.

产品文档

Quality Control & SDS

View current batch:

实验参考方法

Kinase experiment:

Inhibitors (WHI-P180) are pre-incubated in the plate for 15 min with 5 μL kinase and assay buffer at the following concentrations; 13 pM RET and 150 pM KDR. The reaction is initiated by the addition of 5 μL ATP and substrate at 2×final reaction concentrations. For RET, this is 18 μM and 2 μM; for KDR, this is 16 μM and 1 μM, respectively. Reactions are performed at ATP Km for each target. The assay is allowed to proceed at room temperature for 20 min before terminating with the addition of 10 μL HTRF detection buffer containing EDTA supplemented with TK-antibody labelled with Eu3+-Cryptate (1:100 dilution) and streptavidin-XL665 (128 nM). Following incubation at room temperature for 1 h, FRET signal is measured[1].

Cell experiment:

IL3-dependent BaF3 cells are modified to express an activated recombinant kinase. Following removal of IL3, the modified cells are dependent on the activity of the recombinant kinase for survival and proliferation. The BaF3 cell lines, expressing KIF5B-RET and KDR are maintained in RPMI-1640 media containing 10% FBS and appropriate antibiotics. Non-modified BaF3 cells (WT) are maintained in RPMI-1640 media containing 10% FBS and supplemented with 10 ng/mL recombinant mouse IL3. For assessment of compound IC50, cells are plated into 384-well plates at 1500 or 3000 cells per well in 30 μL culture medium and compounds dispensed using an acoustic liquid handling platform. Following incubation of the cells for 48 h at 37 °C in a humidified 5% CO2 atmosphere, viability is determined by addition of 10 μL CellTiter-Glo reagent and measurement of luminescence[1].

Animal experiment:

Mice: A high performance liquid chromatography (HPLC)-based quantitative detection method is used to measure plasma WHI-P180levels in mice. The plasma concentration-time data is fit to a single compartment pharmacokinetic model by using the WinNonlin program to calculate the pharmacokinetic parameters. A cutaneous anaphylaxis model is used to examine the pharmacodynamic effects of WHI-P180 on anaphylaxis-associated vascular hyperpermeability[3].

References:

[1]. Newton R, et al. The discovery of 2-substituted phenol quinazolines as potent RET kinase inhibitors with improved KDR selectivity. Eur J Med Chem. 2016 Apr 13;112:20-32.
[2]. Ghosh S, et al. 4-[3-Bromo-4-hydroxyphenyl)amino]-6,7-dimethoxyquinazolin-1-ium chloride methanol solvateand 4-[(3-hydroxyphenyl)amino]-6,7-dimethoxy-1-quinazolinium chloride. Acta Crystallogr C. 2001 Jan;57(Pt 1):76-8.
[3]. Chen CL, et al. Pharmacokinetics and biologic activity of the novel mast cell inhibitor, 4-(3-hydroxyphenyl)-amino-6,7-dimethoxyquinazoline in mice. Pharm Res. 1999 Jan;16(1):117-22.

产品描述

WHI-P180 is a multi-kinase inhibitor with IC50 values of 4.5 and 66 nM for the human proto-oncogene RET and kinase insert domain receptor (KDR), respectively.1 It also inhibits EGFR (IC50 = 4 μM) and binds to tau-tubulin kinase 1 (TTBK1; Kds = 0.46 and 0.24 μM for phosphorylated and non-phosphorylated TTBK1, respectively).2,3 WHI-P180 inhibits JAK3 and JAK3-driven graft versus host disease responses in mice receiving allogenic bone marrow and splenocyte grafts.2,4 WHI-P180 (25 mg/kg, i.p) inhibits IgE-induced vascular hyperpermeability in a mouse model of passive anaphylaxis.5

1.Newton, R., Bowler, K.A., Burns, E.M., et al.The discovery of 2-substituted phenol quinazolines as potent RET kinase inhibitors with improved KDR selectivityEur. J. Med. Chem.1320-32(2016) 2.Ghosh, S., Jennissen, J.D., Liu, X.P., et al.4-[3-Bromo-4-hydroxyphenyl)amino]-6,7-dimethoxyquinazolin-1-ium chloride methanol solvate and 4-[(3-hydroxyphenyl)amino]-6,7-dimethoxy-1-quinazolinium chlorideActa. Crystallogr. C.57(Pt 1)76-78(2001) 3.Xue, Y., Wan, P.T., Hillertz, P., et al.X-ray structural analysis of tau-tubulin kinase?1 and its interactions with small molecular inhibitorsChemMedChem8(11)1846-1854(2013) 4.Cetkovic-Cvrlje, M., Roers, B.A., Schonhoff, D., et al.Treatment of post-bone marrow transplant acute graft-versus-host disease with a rationally designed JAK3 inhibitorLeuk. Lymphoma.43(7)1447-1453(2002) 5.Chen, C.-L., Malaviya, R., Navara, C., et al.Pharmacokinetics and biologic activity of the novel mast cell inhibitor, 4-(3-hydroxyphenyl)-amino-6,7-dimethoxyquinazoline in micePharm. Res.16(1)117-122(1999)

Chemical Properties

Cas No. 153437-55-9 SDF
别名 Janex 3 hydrochloride;
Canonical SMILES COC1=CC2=NC=NC(NC3=CC=CC(O)=C3)=C2C=C1OC.[H]Cl
分子式 C16H16ClN3O3 分子量 333.77
溶解度 Soluble in DMSO 储存条件 Store at -20°C
General tips 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。
为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。
Shipping Condition 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。

溶解性数据

制备储备液
1 mg 5 mg 10 mg
1 mM 2.9961 mL 14.9804 mL 29.9608 mL
5 mM 0.5992 mL 2.9961 mL 5.9922 mL
10 mM 0.2996 mL 1.498 mL 2.9961 mL
  • 摩尔浓度计算器

  • 稀释计算器

  • 分子量计算器

质量
=
浓度
x
体积
x
分子量
 
 
 
*在配置溶液时,请务必参考产品标签上、MSDS / COA(可在Glpbio的产品页面获得)批次特异的分子量使用本工具。

计算

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % saline
计算重置